Researcher basic information

• Doctor of Clinical Pharmacy, Hokkaido University, Mar. 2020

• https://researchmap.jp/shunsuke_nashimoto?lang=en

• https://jglobal.jst.go.jp/detail?JGLOBAL_ID=202201005449703033

• 202201005449703033

• Clinical Pharmacology and Therapeutics
• Pharmacokinetics
• Therapeutic Drug Monitoring
• Clinical Pharmacometrics
• Reverse Translational Research

• Life Science, Clinical pharmacy
• Life Science, Pharmacology
• Life Science, Pharmaceutical analytical chemistry and physicochemistry

• Bachelor's degree program, School of Pharmaceutical Sciences and Pharmacy
• Master's degree program, Graduate School of Life Science
• Doctoral (PhD) degree program, Graduate School of Life Science

Research activity information

• May 2026, 日本化学療法学会, 日本化学療法学会 学術奨励賞
  Optimization of voriconazole dosage via population pharmacokinetic analysis based on the albumin-bilirubin (ALBI) score of patients with liver dysfunction
  梨本俊亮, 43882539
• Nov. 2025, 日本腎臓病薬物療法学会, 優秀演題賞（口演部門）
  未分画ヘパリン投与下の APTT と 抗Ⅹa活性 の不一致に対する腎機能の影響：探索的後ろ向き観察研究
  三上龍生;早川峰司;今井俊吾;斉藤智誉;佐藤夕紀;柏木仁;梨本俊亮;菅原満;武隈洋
• Oct. 2025, 日本糖尿病学会北海道地方会, メディカルスタッフ優秀演題賞
  ARNI内服中に尿中Cペプチドとインスリン分泌能指標の乖離を認めた2型糖尿病の1例
  小野寺駿;宮前祐士;樋口一世;梨本俊亮;中村昭伸;菅原満;武隈洋
• Jun. 2025, 第8回フレッシャーズ・カンファランス, 優秀演題発表賞
  小腸オルガノイドapical-basal反転培養方法の確立
  浅川綾汰;佐藤夕紀;柏木仁;梨本俊亮;武隈洋;菅原満
• May 2025, 日本薬学会北海道支部, 学生優秀発表賞
  P糖タンパク質の異なる基質認識部位に結合する化合物の構造の探索
  大家悠寿;山田隼大;王子谷健太;柏木仁;佐藤夕紀;梨本俊亮;宮地弘幸;武隈洋;菅原満
• May 2025, 日本薬剤学会, 最優秀発表者賞
  アミノ酸トランスポーターSNAT4を介したエンドサイトーシスによる基質修飾リポソームの取り込み
  松山琳空;佐藤夕紀;藤田聡;丸山真吾;梨本俊亮;柏木仁;武隈洋;菅原満
• Mar. 2025, 日本薬学会, 学生優秀発表賞
  日本の集中治療室における過大腎クリアランス予測スコアの開発と検証
  三上龍生;今井俊吾;早川峰司;佐藤夕紀;柏木仁;梨本俊亮;菅原満;武隈洋
• Mar. 2025, 日本薬学会, 学生優秀発表賞
  ベースラインの血小板数がリネゾリド誘発性血小板減少症の発現に与える影響
  井上優希;柏木仁;佐藤夕紀;梨本俊亮;菅原満;武隈洋
• Jul. 2024, 日本薬学会北海道支部, 学生優秀発表賞
  抗酸化物質投与によるバンコマイシン誘発性腎障害抑制の評価
  武内咲知枝, 佐藤夕紀, 梨本俊亮, 柏木仁, 武隈洋, 菅原満
• Jun. 2023, The Japanese Society of Therapeutic Drug Monitoring, a
  Usefulness of the Albumin-Bilirubin Score in Determining the Initial Dose of Voriconazole for Patients with Liver Cirrhosis
  Shunsuke Nashimoto;Shungo Imai;Mitsuru Sugawara;Yoh Takekuma
• May 2023, 日本薬学会北海道支部, 学生優秀発表賞
  牛乳の利用によるCoQ10吸収改善の可能性の探索
  山内佑紀恵,八巻義朗,佐藤夕紀,柏木 仁,梨本俊亮,武隈 洋,菅原 満
• Mar. 2023, 日本薬学会, 学生優秀発表賞
  国内の医療データベースを利用した0－1歳小児患者におけるバンコマイシン誘発性腎機能障害のリスク要因分析
  宮井貴之,武隈 洋,柏木 仁,佐藤夕紀,梨本俊亮,菅原 満,今井俊吾
• Sep. 2022, The Japanese Society of Pharmaceutical Health Care and Sciences, Postdoctoral Award
  コレステロールトランスポーターNPC1L1を介した食事由来脂質の消化管吸収動態の解析
  Nashimoto Shunsuke
• Aug. 2022, 北海道薬物作用談話会, 若手研究者優秀発表賞
  エチノマイシンとその誘導体のLC-MS/MSによる定量法の確立と体内動態解析
  齋藤香英,武隈 洋,柏木 仁,佐藤夕紀,梨本俊亮,市川 聡,菅原 満
• May 2015, The Academy of Pharmaceutical Science and Technology, THE NAGAI FOUNDATION TOKYO SEVEN STAR PHARMACIST CANDIDATE AWARD 2015
  The effect of ezetimibe (Zetia ® ) on absorption of α-tocopherol
  Shunsuke Nashimoto;Yuki Sato;Masato Sumi;Yoh Takekuma;Mitsuru Sugawara

• Development of a method of liquid chromatography coupled with tandem mass spectrometry for simultaneous determination of hyaluronan oligosaccharide in plasma.
  Nao Takabayashi; Yuki Sato; Kuma Aoyagi; Shunsuke Nashimoto; Hitoshi Kashiwagi; Yoh Takekuma; Mitsuru Sugawara
  Food research international (Ottawa, Ont.), 236, 119273, 119273, 31 Jul. 2026, [International Magazine]
  English, Scientific journal, Hyaluronan (HA) exists in the body with various molecular weights ranging from several hundred to several million. Recently the physiological functions of HA oligosaccharides, in addition to high-molecular weight HA, have been reported. It is important to clarify the relationship between physiological function and pharmacokinetics. When HA is ingested orally, most of it is broken down into HA oligosaccharides less than 8-mers by the gut microbiota and absorbed. However, there is no method to simultaneously determine these HA oligosaccharides. This study aimed to elucidate the pharmacokinetics of exogenous HA, in plasma samples, by developing a simple pretreatment and highly sensitive simultaneous determination method for HA less than 8-mers. First, carboxy groups of HA oligosaccharides were derivatized with a condensing reagent (DMT-MM) and Girard's reagent P. After pretreatment by solid-phase extraction using hydrophilic interaction, peaks of HA 2, 4, 6 and 8-mer were detected by LC-MS/MS. Validation studies were conducted for this method. Additionally, plasma concentrations of HA were determined after oral administration of HA formulation to rats. We confirmed by MS scan that the derivatized HA oligosaccharides could be analyzed by the developed quantitative method and identified the peak of derivatized HA oligosaccharides. The MS/MS conditions were optimized, and a calibration curve was generated, which showed good linearity for HA 4, 6, and 8-mer. This method was valid and enabled measurement of HA 4, 6, and 8-mer concentrations in plasma. This simultaneous analytical method can reduce experiment time compared to conventional methods.
• Risk factors of docetaxel-induced peripheral edema in non-small cell lung cancer treatment: a multi-institutional cohort study.
  Shinsuke Yamashita; Yoshitaka Saito; Shinya Tamaki; Daisuke Hirate; Karin Wakai; Itsuki Yonezawa; Honoka Hirasawa; Hitoshi Kashiwagi; Yuki Sato; Shungo Imai; Shunsuke Nashimoto; Jun Sakakibara-Konishi; Yasushi Shimizu; Ichiro Kinoshita; Ryo Takagi; Mitsuru Sugawara; Yoh Takekuma
  Japanese journal of clinical oncology, 26 Jul. 2026, [International Magazine]
  English, Scientific journal, BACKGROUND: Peripheral edema is an adverse event associated with docetaxel (DTX). However, previous studies on DTX-induced peripheral edema have been limited to patients with breast cancer. Therefore, evaluation of symptoms in other cancer types is essential. We aimed to identify the factors associated with this symptom in patients with non-small cell lung cancer (NSCLC). METHODS: This retrospective multicenter observational study evaluated 170 patients with NSCLC who received DTX between April 2014 and December 2024. The primary endpoint was factors associated with grade ≥ 2 DTX-induced peripheral edema during up to seven cycles. Additionally, we evaluated the factors for all-grade symptoms. RESULTS: The incidences of grade ≥ 2 and all-grade DTX-induced peripheral edema were 13.5% and 30.0%. The median cumulative DTX dose at symptom onset was 144 (interquartile range, 60-254) mg/m2 for grade ≥ 2 DTX-induced peripheral edema and 120 (60-210) mg/m2 for all-grade symptoms. The Fine-Gray sub-distribution hazard models revealed that the co-administration of ramucirumab (RAM) was significantly associated with the incidence of DTX-induced peripheral edema (grade ≥ 2: sub-distribution hazard ratio [SDHR], 3.51; 95% confidence interval [CI], 1.34-9.24; P = 0.011) (all-grade: SDHR, 2.17; 95% CI, 1.20-3.92; P = 0.011). The Gray's test demonstrated that the cumulative incidence of DTX-induced peripheral edema was significantly higher in the DTX + RAM group than in the DTX monotherapy group (P = 0.003 and < 0.001 for grade ≥ 2 and all-grade symptoms, respectively). CONCLUSIONS: We revealed that co-administration of RAM is a risk factor for DTX-induced peripheral edema in patients with NSCLC.
• Hyperfiltration in Critically Ill Older Adults: Incidence, Risk Factors, Time Course, and Predictive Performance of Kidney Function Estimation.
  Ryusei Mikami; Shungo Imai; Mineji Hayakawa; Gaku Izumi; Hitoshi Kashiwagi; Yuki Sato; Shunsuke Nashimoto; Takeshi Wada; Mitsuru Sugawara; Yoh Takekuma
  Pharmacotherapy, 46, 6, e70153, Jun. 2026, [International Magazine]
  English, Scientific journal, STUDY OBJECTIVE: This study aimed to evaluate the incidence, associated risk factors, time course, and predictive performance of kidney function estimation equations for hyperfiltration in critically ill older adults. METHODS: This retrospective observational study evaluated 325 patients (median age, 76 years) admitted to the intensive care unit (ICU) of a tertiary-care university hospital, for a total of 2934 patient-days. The hyperfiltration threshold was defined using measured creatinine clearance (Clcr) > -0.883 × age + 167.398. Independent factors associated with hyperfiltration were identified via a multivariable logistic regression model, and time to onset and duration were evaluated using Kaplan-Meier curves. Additionally, the predictive performance of the measured Clcr was assessed using the Cockcroft-Gault equation. Bias was analyzed using the Bland-Altman analysis, and accuracy was evaluated using the percentage within 30% of the measured Clcr (P30). RESULTS: Hyperfiltration occurred in 56% of the patients. Risk factors included male sex, high body mass index, trauma-related admission, vasopressor use, and low serum creatinine levels. The median time from ICU admission to hyperfiltration onset was 5 days, and the median duration of hyperfiltration episodes was 8 days. The Cockcroft-Gault equation substantially underestimated measured Clcr in patients with hyperfiltration. Even among those whose measured Clcr did not meet the conventional augmented renal clearance (ARC) threshold (> 130 mL/min), the equation exhibited a clinically significant negative bias (-35 mL/min) with limited accuracy (P30: 39%). This underestimation was even more pronounced in patients meeting the ARC criteria (bias: -62 mL/min; P30: 27%). CONCLUSIONS: Hyperfiltration is highly prevalent in critically ill older adults. The Cockcroft-Gault equation substantially underestimated actual kidney function, even without meeting the ARC criteria. Continuous monitoring of the measured Clcr is recommended to avoid inappropriate medication dose reductions due to underestimation.
• Creatinine- and cystatin C-based population pharmacokinetic models for predicting mycophenolic acid clearance in patients with autoimmune diseases.
  Shunsuke Nashimoto; Masashi Miyamae; Shun Onodera; Mitsuru Sugawara; Yoh Takekuma
  European journal of clinical pharmacology, 82, 4, 18 Mar. 2026, [International Magazine]
  English, Scientific journal
• Linezolid-Induced Serotonin Release from QGP-1 Cells.
  Takezo Tsutsumi; Hitoshi Kashiwagi; Shungo Imai; Yuki Sato; Shunsuke Nashimoto; Mitsuru Sugawara; Yoh Takekuma
  Drug research, 02 Mar. 2026, [International Magazine]
  English, Scientific journal, Nausea and vomiting are commonly reported side effects of long-term linezolid therapy, which is indispensable for tuberculosis and osteoarticular infections. Since the mechanism underlying the development of nausea and vomiting during linezolid treatment is unknown, this study aimed to explore the mechanisms by focusing on the monoamine oxidase-inhibiting effect of linezolid.In vitro serotonin release assays were performed using QGP-1 cells as a surrogate for enterochromaffin cells exposed to linezolid, the monoamine oxidase inhibitor clorgyline, and the known emetogenic agent cisplatin. Serotonin concentrations in the solutions were measured using an enzyme-linked immunosorbent assay. Clorgyline and cisplatin were administered simultaneously with linezolid to elucidate the serotonin release mechanism and confirm the synergistic effects. The intracellular Ca2+assays using Fura‑2 were also performed to assess whether serotonin release is mediated by Ca2+‑dependent exocytosis.Linezolid exposure significantly increased serotonin release from QGP-1 cells in concentration- and time-dependent manners. Serotonin release also increased in the clorgyline exposure group, and the release of serotonin in the linezolid/clorgyline co-exposure group was higher than that in the single-exposure groups. In contrast, no significant serotonin release or synergistic effects were observed in the cisplatin/linezolid-exposed groups. The Ca2+assays demonstrated that linezolid exposure did not change intracellular Ca2+levels.Serotonin release was observed when QGP-1 cells were exposed to linezolid, an effect similar to that observed with the potent monoamine oxidase A inhibitor clorgyline. Furthermore, the Ca2+assays indicated that linezolid‑induced serotonin release occurs independently of Ca2+‑dependent exocytosis.
• Temporal effects of empirical round-up of serum creatinine on the accuracy of estimated kidney function after critical illness.
  R Mikami; S Imai; M Hayakawa; H Kashiwagi; Y Sato; S Nashimoto; M Sugawara; Y Takekuma
  Die Pharmazie, 80, 9, 93, 101, 01 Oct. 2025, [International Magazine]
  English, Scientific journal, This study aimed to evaluate the temporal effect of a serum creatinine (SCr) correction intervention in critically ill patients with daily muscle wasting. A total of 5,355 critical care days in 574 patients with creatinine clearance (Clcr) and glomerular filtration rate (GFR) measured and estimated simultaneously were included. The primary endpoint was the difference in accuracy over time of the estimated Clcr/GFR relative to the measured Clcr. The CG equation was used to estimate Clcr, and the MDRD and CKD-EPI-equations were used to estimate GFR. Estimated Clcr(round-up)/GFR(round-up) indicates the estimated Clcr/GFR calculated using the rounded up value if SCr was <0.6 mg/dL. Bias was analyzed using Bland-Altman analysis, correlation using Spearman's rank correlation coefficient, and accuracy using percentage within 30% of the measured Clcr (P30). The CKD-EPI equation showed a large underestimation bias in the early period, whereas the CG and MDRD equations indicated large overestimation biases in the later period. Round-up correction increased the underestimation bias in the early period of the CG(round-up) and MDRD(round-up) equations, but decreased the overestimation bias in the later period. The limits of agreements for the CG(round-up) and MDRD(round-up) equations were narrower, although not consistently acceptable. The correlations were stronger for the CG(round-up) and MDRD(round-up) equations. Accuracy did not improve with the corrective intervention. Conclusion: SCr round-up correction increased the underestimation of kidney function in the early phase, but mitigated overestimation in the later phase. The limits of agreement remained unacceptable, and the accuracy did not improve.
• Temporal effects of errors in estimating kidney function after critical illness on drug dosing categories.
  Ryusei Mikami; Shungo Imai; Mineji Hayakawa; Kento Sabashi; Hitoshi Kashiwagi; Yuki Sato; Shunsuke Nashimoto; Mitsuru Sugawara; Yoh Takekuma
  British journal of clinical pharmacology, 26 Aug. 2025, [International Magazine]
  English, Scientific journal, AIMS: This study aimed to clarify how the trajectories of the Cockcroft-Gault (CG), Modification of Diet in Renal Disease (MDRD) and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations differ from measured creatinine clearance (Clcr) and to determine their impact on drug dosing categories in critically ill patients. METHODS: We used data from 5355 days following critical illness to estimate the trajectories of the above-mentioned kidney function equations using a linear mixed model. In addition, we determined whether the CG, MDRD and CKD-EPI equations would change drug dosing categories (<15, 15-29, 30-59, 60-89, 90-119, 120-149, or ≥150 mL/min) over time compared with that observed using measured Clcr. RESULTS: The rate of change relative to baseline in measured Clcr remained almost unchanged during the 28 days of observation (-0.02 [95% confidence interval, CI: -0.19-0.14] mL/min/1.73 m2/day). In contrast, all indirect kidney function estimating equations showed a time-dependent increase in the rate of change, which was largest for the CG equation, followed by the MDRD and CKD-EPI equations (+2.00 [95% CI: 1.89-2.12], +1.50 [95% CI: 1.34-1.67] and +0.77 [95% CI: 0.61-0.93] mL/min/1.73 m2/day, respectively). More than half of the CG, MDRD and CKD-EPI equations showed discrepancies with the measured Clcr and drug dosing categories, with underestimation in the early phases and overestimation in the later phases being more common. CONCLUSION: Creatinine-based indirect kidney function estimation equations increased over time, indicating erroneous drug dosing categories on over half of the critical care days.
• The effect of sacubitril/valsartan on urinary C-peptide excretion and endogenous insulin secretory capacity in a patient with type 2 diabetes: a case report.
  Shun Onodera; Masashi Miyamae; Issei Higuchi; Shunsuke Nashimoto; Akinobu Nakamura; Mitsuru Sugawara; Yoh Takekuma
  Journal of pharmaceutical health care and sciences, 11, 1, 75, 75, 17 Aug. 2025, [International Magazine]
  English, Scientific journal, BACKGROUND: The evaluation of endogenous insulin secretory capacity is important in the selection of diabetes treatment. C-peptide, which is secreted in equivalent amounts as insulin, is a versatile test for this evaluation. Urinary C-peptide is widely used because it is less invasive. Sacubitril/valsartan, used to treat hypertension and chronic heart failure, has been reported to increase urinary C-peptide levels; however, its effect on endogenous insulin secretion remains unknown. In this report, we present a case in which insulin secretory capacity was evaluated according to a glucagon stimulation test in addition to urinary C-peptide levels in a patient receiving sacubitril/valsartan. CASE PRESENTATION: A male patient in his 50s with type 2 diabetes and hypertension, without renal dysfunction, was treated with sacubitril/valsartan. The results of the glucagon stimulation test showed a C-peptide change of 2.28, and the C-peptide index on the same day was 1.25, indicating normal endogenous insulin secretory capacity. In contrast, 24-h urinary C-peptide excretion was abnormally high at 615.2 µg/day. After discontinuation of sacubitril/valsartan, urinary C-peptide excretion decreased over time (615.2 to 369.0 µg/day), but blood glucose levels did not increase during this period. CONCLUSIONS: In this case, 24-h urinary C-peptide excretion was abnormally elevated despite preserved endogenous insulin secretory capacity, as assessed by the glucagon stimulation test. Although this observation is based on a single case and cannot be generalized, it suggests that sacubitril/valsartan may interfere with the interpretation of urinary C-peptide levels. Therefore, in such clinical contexts, dynamic tests such as the glucagon stimulation test may serve as a useful adjunct to avoid potential overestimation of insulin secretory capacity when relying solely on urinary C-peptide levels.
• Optimization of voriconazole dosage via population pharmacokinetic analysis based on the albumin-bilirubin (ALBI) score of patients with liver dysfunction.
  Shunsuke Nashimoto; Mitsuru Sugawara; Yoh Takekuma
  Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 102766, 102766, 02 Jul. 2025, [International Magazine]
  English, Scientific journal, INTRODUCTION: Voriconazole (VRCZ) is an antifungal agent used to treat refractory fungal infections. Its dosage is adjusted based on the individual liver function. In this study, we aimed to establish a population pharmacokinetic analysis model based on the albumin-bilirubin (ALBI) score to objectively assess the liver function using only albumin and total bilirubin levels as covariates. METHODS: In total, 126 plasma samples of 16 patients with liver dysfunction who received oral VRCZ between 2012 and 2022 were analyzed in this study. Phoenix NLME software was used for population pharmacokinetic analysis, and Monte Carlo simulations were performed to determine the optimal dosing regimen to achieve the target blood VRCZ concentration. RESULTS: Blood VRCZ concentration was described using a 1-compartment model with lag time. In the final model, objective function was significantly decreased upon ALBI score incorporation into clearance. Monte Carlo simulations showed that the optimal dosing schedules were 100 mg twice daily, 75 mg twice daily, and 50 mg twice daily for ALBI scores of -3, -2, and -1, respectively. Notably, for an ALBI score of 0, target blood VRCZ concentration was exceeded, even a dosing regimen of 50 mg twice daily. CONCLUSION: To the best of our knowledge, this study is the first to incorporate the ALBI score into a population pharmacokinetic model for VRCZ. Our simulation results suggest that the maintenance dose should be reduced based on the ALBI score. Furthermore, our findings highlight the potential use of the ALBI score for optimal drug dosage design.
• Evaluation of Transport Activity Using Mouse Jejunal Epithelial Cell Monolayer Culture System.
  Yoshiki Sasagawa; Riho Kamishima; Hitoshi Kashiwagi; Yuki Sato; Shunsuke Nashimoto; Yoh Takekuma; Mitsuru Sugawara
  Biological & pharmaceutical bulletin, 48, 8, 1199, 1206, 2025, [Domestic magazines]
  English, Scientific journal, Caco-2 cells, derived from colorectal cancer cells, are generally used to evaluate drug absorption in the gastrointestinal tract. However, differences between Caco-2 and normal intestinal cells have been observed. Cells cultured directly from crypts are maintained in their biological state. Therefore, we developed a rapid and easy method of monolayer culture of epithelial cells isolated from the jejunum of mice. We analyzed the usefulness of the jejunal epithelial cell monolayer culture system as a research tool and evaluated changes in the transport activity and mRNA expression of transporters. We focused on P-glycoprotein (P-gp) and peptide transporter 1 (Pept1) as representative transporters expressed in the small intestine. A P-gp inhibitor significantly enhanced the accumulation of Rhodamine 123 (Rho123), a substrate of P-gp, indicating that the transport activity of P-gp could be evaluated. Uptake of glycylsarcosine, a Pept1 substrate, significantly decreased in the presence of the Pept1 inhibitor, indicating that the transport activity of Pept1 could be evaluated. Rho123 accumulation significantly decreased in the group treated with calcitriol, an inducer of P-gp and Cyp3a11, suggesting that changes in P-gp expression could be evaluated. Furthermore, we examined whether mRNA expression levels of transporters and drug-metabolizing enzyme were altered. In the calcitriol-supplemented group, P-gp and Cyp3a11 mRNA levels significantly increased. However, no significant differences were observed in Pept1 mRNA levels. Overall, the jejunal epithelial cell monolayer culture system developed from intestinal tissues is a useful research tool for assessing the transport activities and expression variabilities of transporters.
• Actual Use of Budesonide Enteric-Coated Capsules for Crohn's Disease in Japan: Analysis of Health Insurance Big Data.
  Keiji Yagisawa; Atsuhito Kubota; Shungo Imai; Shunsuke Nashimoto; Yuki Sato; Hitoshi Kashiwagi; Atsuo Maemoto; Mitsuru Sugawara; Yoh Takekuma
  Biological & pharmaceutical bulletin, 48, 1, 33, 38, 2025, [Domestic magazines]
  English, Scientific journal, Using a large health insurance database in Japan, we examined the real-world usage of budesonide enteric-coated capsules (BUD) in treating Crohn's disease. We analyzed data from the Japan Medical Data Center claims database for Crohn's disease patients prescribed BUD from April 2016 to March 2021, focusing on prescription status, adverse events (AEs), monitoring tests, and concomitant medications over 2 years following BUD initiation. Patients were categorized into two groups based on BUD usage duration: ≤1 year and >1 year. Of the 7364 registered patients, 1049 (14.2%) were prescribed BUD. Among the 562 followed for 2 years, 505 (89.9%) used BUD for ≤1 year and 57 (10.1%) for >1 year. Over 70% of the patients used at least one biologic, and more than 20% used at least two. The proportions of new thiopurine initiation were 22 and 9% in the ≤1-year and >1-year groups, respectively (p = 0.0181). We did not identify any obvious increase in AEs from long-term BUD use within the confines of our study design. However, regardless of prescription duration, over half of the patients lacked hepatitis B virus screening, glycated hemoglobin measurement, adrenal function quantification, or bone densitometry. Usage of strong CYP3A4 inhibitors was more frequent among patients in the BUD >1-year group. This study revealed that numerous Japanese patients received long-term BUD prescriptions. Although no apparent increase in AEs from long-term BUD was detected, we identified inadequate monitoring of AEs and drug interactions, as well as insufficient use of steroid-sparing agents.
• Development and validation of the prediction score for augmented renal clearance in critically Ill Japanese adults.
  Ryusei Mikami; Shungo Imai; Mineji Hayakawa; Hitoshi Kashiwagi; Yuki Sato; Shunsuke Nashimoto; Mitsuru Sugawara; Yoh Takekuma
  Journal of pharmaceutical health care and sciences, 10, 1, 69, 69, 06 Nov. 2024, [International Magazine]
  English, Scientific journal, BACKGROUND: Augmented renal clearance (ARC) decreases the therapeutic concentration of drugs excreted by the kidneys in critically ill patients. Several ARC prediction models have been developed and validated; however, their usefulness in Japan has not been comprehensively investigated. Thus, we developed a unique ARC prediction model for a Japanese mixed intensive care unit (ICU) population and compared it with existing models. METHODS: This retrospective study enrolled a mixed ICU population in Japan from January 2019 and June 2022. The primary outcome was the development and validation of a model to predict ARC onset based on baseline information at ICU admission. Patients admitted until May 2021 were included in the training set, and external validation was performed on patients admitted thereafter. A multivariate logistic regression model was used to develop an integer-based predictive scoring system for ARC. The new model (the JPNARC score) was externally validated along with the ARC and Augmented Renal Clearance in Trauma Intensive Care (ARCTIC) scores. RESULTS: A total of 2,592 critically ill patients were enrolled initially, with 651 patients finally included after excluding 1,941 patients. The training and validation datasets comprised 456 and 195 patients, respectively. Multivariate analysis was performed to develop the JPNARC score, which incorporated age, sex, serum creatinine, and diagnosis upon ICU admission (trauma or central nervous system disease). The JPNARC score had a larger area under the receiver operating characteristic curve than the ARC and ARCTIC scores in the validation dataset (0.832, 0.633, and 0.740, respectively). CONCLUSIONS: An integer-based scoring system was developed to predict ARC onset in a critically ill Japanese population and showed high predictive performance. New models designed to predict the often-unrecognized ARC phenomenon may aid in the decision-making process for upward drug dosage modifications, especially in resource- and labor-limited settings.
• Clinical research for saliva-based therapeutic drug monitoring of linezolid.
  Yuki Inoue; Hitoshi Kashiwagi; Yuki Sato; Shunsuke Nashimoto; Tsutomu Endo; Masahiko Takahata; Miki Komatsu; Mitsuru Sugawara; Yoh Takekuma
  British journal of clinical pharmacology, 10 Oct. 2024, [International Magazine]
  English, Scientific journal, AIMS: Linezolid is primarily used to treat of methicillin-resistant Staphylococcus aureus and multidrug-resistant tuberculosis infections. Thrombocytopenia due to linezolid usage is a concern, and therapeutic drug monitoring has been reported to be effective in its prevention. Plasma concentrations provide valuable information for treatment decisions; however, collecting plasma samples can be burdensome for both patients and healthcare providers. Therefore, there is interest in saliva as an alternative for monitoring, considering its potential to replace plasma samples. METHODS: Patients hospitalized at Hokkaido University Hospital and Hokkaido Spinal Cord Injury Center between April 2022 and July 2024, who received oral or intravenous linezolid treatment, were enrolled. The concentrations of linezolid were simultaneously measured in plasma and saliva samples. We determined the concentration profiles of linezolid in the saliva and examined the correlation between saliva and plasma linezolid concentrations. RESULTS: Eighteen patients receiving linezolid were enrolled. The average of saliva/plasma (S/P) concentration ratios of linezolid were 1.018. A strong correlation was found between the salivary and plasma concentrations of linezolid (R = .833, P < .001). Notably, in patients receiving intravenous administration of linezolid, the correlation was even more pronounced (R = .885, P < .001). Additionally, when focusing on the S/P ratio of the trough concentrations in the morning and at night, the S/P ratios at night were much closer to 1.0. CONCLUSION: The concentrations of linezolid in plasma and saliva were similar, indicating their potential applicability in clinical settings. The monitoring of linezolid concentrations in saliva has been shown to be particularly suitable for patients receiving intravenous administration.
• Exploring the impact of baseline platelet count on linezolid-induced thrombocytopenia: a retrospective single-center observation study.
  Yuki Inoue; Hitoshi Kashiwagi; Yuki Sato; Shunsuke Nashimoto; Mitsuru Sugawara; Yoh Takekuma
  International journal of clinical pharmacy, 04 Oct. 2024, [International Magazine]
  English, Scientific journal, BACKGROUND: Patients treated with linezolid (LZD) frequently develop thrombocytopenia, and previous studies have identified the risk factors for this condition. However, the relationship between the development of LZD-induced thrombocytopenia and baseline platelet count has varied according to different reports. AIM: To explore the relationship between platelet count and the development of LZD-induced thrombocytopenia. METHOD: Patients who underwent LZD at Hokkaido University Hospital in Japan from September 2008 to March 2023 were included. We collected data on patient characteristics and platelet counts at baseline and during LZD therapy from the electronic medical records. Thrombocytopenia was defined as a decrease in platelet count by 30% or more from baseline, or a platelet level < 100,000/µL. RESULTS: Two hundred and ninety-five patients who received LZD were included in this study, of whom 34.9% developed thrombocytopenia. In the early days of LZD treatment, the thrombocytopenia group showed a nearly 5% decrease in platelet count, while the non-thrombocytopenia group exhibited an increase of over 5%. Additionally, focusing on early onset thrombocytopenia (within 5 days), a baseline platelet count of < 150,000/µL was identified as a risk factor for early thrombocytopenia. Conversely, it was also observed that 24.7% of patients with a baseline platelet count ≥ 150,000/µL still developed early thrombocytopenia. CONCLUSION: Our findings suggest that while a baseline platelet count of < 150,000/µL is a risk factor for the early onset of thrombocytopenia, vigilant monitoring of platelet counts by clinical pharmacists in the early stages of LZD treatment is essential, regardless of baseline platelet levels.
• Decrease in Mycophenolic Acid Plasma Level by Sacubitril/Valsartan in a Lupus Nephritis Patient: A Case Report
  Shunsuke Nashimoto; Masashi Miyamae; Issei Higuchi; Michihito Kono; Maria Tada; Tatsuya Atsumi; Mitsuru Sugawara; Yoh Takekuma
  Case Reports in Nephrology and Dialysis, 14, 1, 30, 35, S. Karger AG, 28 Feb. 2024, [Peer-reviewed], [Lead author]
  English, Scientific journal, <b><i>Introduction:</i></b> Mycophenolate mofetil (MMF), an inactive prodrug of mycophenolic acid (MPA), is an immunosuppressive drug used widely in the treatment of lupus nephritis. In this case report, the area under the blood concentration time curve (AUC) of MPA was significantly decreased by the concomitant use of sacubitril/valsartan. <b><i>Case Presentation:</i></b> The patient was a man in his 40s with a diagnosis of lupus nephritis class IVa/c+V. MMF dose was 1.5 g/day at admission, and AUC of MPA on day 14 was 25.1 μg⋅h/mL. Owing to poor blood pressure control, sacubitril/valsartan was initiated at 97/103 mg/day on day 29. On day 37, AUC of MPA was significantly decreased to 8.7 μg⋅h/mL, suggesting drug interaction with the newly initiated sacubitril/valsartan. Sacubitril/valsartan was decreased to 49/51 mg/day, and AUC of MPA on day 67 was 37.6 μg⋅h/mL, achieving the target range. The final MMF dose was set at 1.75 g/day. A possible mechanism of drug interaction between sacubitril/valsartan and MPA involves an organic anion transporting polypeptide (OATP). The inhibition of OATPs by sacubitril may have interrupted the enterohepatic circulation of MPA, resulting in a lower plasma concentration. <b><i>Conclusion:</i></b> Since lupus nephritis is often associated with hypertension, the drug interaction observed in this report may also occur in other cases. However, it is impossible to conclude that the decrease in plasma MPA levels was due to the concomitant use of sacubitril/valsartan, and more cases and basic findings are needed.
• Platelets Affect the Activity of Amino Acid Transporter SNAT4 in HuH-7 Human Hepatoma Cells.
  Hitoshi Kashiwagi; Yuki Sato; Shunsuke Nashimoto; Shungo Imai; Yoh Takekuma; Mitsuru Sugawara
  Biological & pharmaceutical bulletin, 47, 3, 652, 659, 2024, [Domestic magazines]
  English, Scientific journal, Platelets have been reported to exert diverse actions besides hemostasis and thrombus formation in the body. However, whether platelets affect transporter activity remains to be determined. In this study, we examined the effects of platelets on the activity of amino acid transporter system A, which is known to be changed by various factors, and we clarified the mechanism by which platelets affect system A activity. Among system A subtypes, we found that sodium-coupled neutral amino acid transporter (SNAT) 4 played a central role in the transport activity of system A in HuH-7 human hepatoma cells. Interestingly, platelets showed a biphasic effect on system A activity: activated platelet supernatants (APS) including the granule contents released from platelets downregulated system A activity at lower concentrations and the downregulation was suppressed at higher concentrations. The downregulation was due to a decrease in the affinity of SNAT4 for its substrate and not a decrease in the SNAT4 abundance on the plasma membrane. In addition, APS did not decrease the expression level of SNAT4 mRNA. On the other hand, platelets did not affect system A activity when the platelet suspension was added to HuH-7 cells. These results indicate that platelets indirectly affect the transport activity of system A by releasing bioactive substances but do not directly affect it by binding to HuH-7 cells.
• Monitoring Salivary Concentrations of Tedizolid and Linezolid Using Rats.
  Yuki Inoue; Yuki Sato; Hitoshi Kashiwagi; Shunsuke Nashimoto; Mitsuru Sugawara; Yoh Takekuma
  European journal of drug metabolism and pharmacokinetics, 48, 4, 387, 395, Jul. 2023, [Peer-reviewed], [International Magazine]
  English, Scientific journal, BACKGROUND AND OBJECTIVE: Therapeutic drug monitoring (TDM) is an effective tool for the management of patients who are administered linezolid. The use of saliva for TDM has potential advantages over the use of plasma; however, only a few reports have compared drug concentrations in the saliva and plasma. Moreover, there are no reports on the salivary concentration of tedizolid, an oxazolidinone antibiotic similar to linezolid. In the present study, the concentrations of tedizolid and linezolid in rat submandibular saliva were compared with those measured in the plasma. METHODS: Tedizolid (10 mg/kg, n = 6) and linezolid (12 mg/kg, n = 5) were administered via the rat tail vein. Submandibular saliva and plasma samples were collected for up to 8 h after the initiation of drug administration, and assayed for the concentrations of tedizolid and linezolid. RESULTS: A strong correlation was found between the saliva and plasma concentrations of tedizolid (r = 0.964, p < 0.001) and linezolid (r = 0.936, p < 0.001). The value of tedizolid maximum concentration of drug (Cmax) was 0.99 ± 0.08 µg/mL in the saliva and 14.46 ± 1.71 µg/mL in the plasma. Meanwhile, the Cmax of linezolid was 8.01 ± 1.42 µg/mL in the saliva and 13.00 ± 1.90 µg/mL in the plasma. According to these results, the saliva/plasma concentration ratios of tedizolid and linezolid in rats were 0.0513 ± 0.0080 and 0.6341 ± 0.0339, respectively. CONCLUSIONS: Considering the correlation between saliva and plasma concentrations of tedizolid and linezolid, as well as the characteristics of saliva, the results of this study suggest that saliva is a useful matrix for TDM.
• Usefulness of the Albumin–Bilirubin Score in Determining the Initial Dose of Voriconazole for Patients with Liver Cirrhosis
  Shunsuke Nashimoto; Shungo Imai; Mitsuru Sugawara; Yoh Takekuma
  Biological and Pharmaceutical Bulletin, 46, 2, 230, 236, Pharmaceutical Society of Japan, 01 Feb. 2023, [Peer-reviewed], [Lead author]
  English, Scientific journal
• Risk Factor Analysis of Vancomycin-Induced Nephrotoxicity in Paediatric Patients Aged 0-1 Year Using Japanese Medical Database.
  Takayuki Miyai; Yoh Takekuma; Hitoshi Kashiwagi; Yuki Sato; Shunsuke Nashimoto; Mitsuru Sugawara; Shungo Imai
  Biological & pharmaceutical bulletin, 46, 6, 817, 823, 2023, [Domestic magazines]
  English, Scientific journal, Vancomycin (VCM)-induced nephrotoxicity (VIN) is a major side effect in paediatric patients. However, most studies are limited to patients aged 0-18 years. We evaluated the risk factors of VIN in patients aged 0-1 year using Japanese electronic medical record database. We used RWD database which was contained electronic medical records and claims data of approximately 20 million people from 160 medical institutions. We targeted hospitalized patients who were administered VCM between June 2000 and December 2020. VIN was defined by two criteria: Criterion 1 was an increase in serum creatinine (Scr) ≥ 0.5 mg/dL or 50% during VCM treatment period compared to the Scr baseline; and criterion 2 was an increase in Scr ≥50% within seven days or Scr ≥0.3 mg/dL within two days during VCM treatment. The risk factors of VIN were evaluated using multivariate logistic regression analysis. We analysed 446 patients; patients with VIN in Criteria 1 and 2 were 33 and 58, respectively. In Criterion 1, multivariate logistic regression analysis identified four independent factors with p-value <0.05 (VCM concentration ≥20 mg/L, amphotericin B (AMPH-B), piperacillin-tazobactam (TAZ/PIPC), and vasopressor drugs). In Criterion 2, multivariate logistic regression analysis identified concomitant use of vasopressor drugs with p-value <0.05. Therefore, concomitant use of vasopressor drugs was suggested to affect the risk of VIN in patients aged 0-1 year. The findings may help in developing estimation models to assess the risk of VIN in paediatric patients.
• A new system to evaluate characteristics of Niemann-Pick C1 Like 1-mediated cholesterol transport using Xenopus laevis oocytes
  Shunsuke Nashimoto; Saori Yagi; Naoki Takeda; Miku Nonaka; Yoh Takekuma; Mitsuru Sugawara; Yuki Sato
  Biochimica et Biophysica Acta (BBA) - Biomembranes, 1863, 2, 183508, 183508, Elsevier BV, Feb. 2021, [Peer-reviewed], [Lead author]
  English, Scientific journal
• Transport via Niemann-Pick C1 Like 1 contributes to the intestinal absorption of ubiquinone
  Shunsuke Nashimoto; Yuto Takekawa; Yoh Takekuma; Mitsuru Sugawara; Yuki Sato
  Drug Metabolism and Pharmacokinetics, 35, 6, 527, 533, Elsevier BV, Dec. 2020, [Peer-reviewed], [Lead author]
  English, Scientific journal
• コレステロールトランスポーターNPC1L1を介した脂溶性抗酸化物質の消化管吸収動態の解析
  梨本俊亮
  Mar. 2020, [Peer-reviewed], [Lead author]
  Japanese, Doctoral thesis
• Enhancement of lymphatic transport of lutein by oral administration of a solid dispersion and a self-microemulsifying drug delivery system
  Yuki Sato; Tatsuru Joumura; Shunsuke Nashimoto; Sayaka Yokoyama; Yoh Takekuma; Hideto Yoshida; Mitsuru Sugawara
  European Journal of Pharmaceutics and Biopharmaceutics, 127, 171, 176, Elsevier BV, Jun. 2018, [Peer-reviewed]
  English, Scientific journal
• Inhibitory effect of ezetimibe can be prevented by an administration interval of 4 h between α-tocopherol and ezetimibe
  Shunsuke Nashimoto; Yuki Sato; Yoh Takekuma; Mitsuru Sugawara
  Biopharmaceutics & Drug Disposition, 38, 4, 280, 289, Wiley, May 2017, [Peer-reviewed], [Lead author]
  English, Scientific journal

• ANRI内服中に尿中Cペプチドとインスリン分泌能指標の乖離を認めた2型糖尿病の1例
  小野寺 駿; 宮前 祐士; 樋口 一世; 梨本 俊亮; 中村 昭伸; 菅原 満; 武隈 洋, 糖尿病, 69, 2, 53, 53, Feb. 2026
  (一社)日本糖尿病学会, Japanese
• 臨床業務で経験した相互作用 ループス腎炎患者におけるサクビトリルバルサルタンとの併用によるミコフェノール酸の血中濃度低下とその機序の解析
  梨本 俊亮, 医薬品相互作用研究, 49, 3, 130, 130, Oct. 2025
  (一社)医薬品相互作用研究会, Japanese
• 未分画ヘパリンモニタリングにおけるAPTTと抗Xa活性の不一致に対する腎機能の影響 探索的後ろ向き観察研究
  三上 龍生; 早川 峰司; 今井 俊吾; 斉藤 智誉; 佐藤 夕紀; 柏木 仁; 梨本 俊亮; 菅原 満; 武隈 洋, 日本腎臓病薬物療法学会誌, 14, 特別号, S172, S172, Sep. 2025
  (一社)日本腎臓病薬物療法学会, Japanese
• 非小細胞肺がん患者におけるドセタキセル誘発性浮腫の要因分析
  山下 慎介; 齋藤 佳敬; 今井 俊吾; 柏木 仁; 佐藤 夕紀; 梨本 俊亮; 榊原 純; 清水 康; 木下 一郎; 武隈 洋; 菅原 満, 日本臨床腫瘍薬学会雑誌, 41, 139, 139, May 2025
  (一社)日本臨床腫瘍薬学会, Japanese
• アミノ酸トランスポーターSNAT4を介したエンドサイトーシスによる基質修飾リポソームの取り込み
  松山 琳空; 佐藤 夕紀; 藤田 聡; 丸山 真吾; 梨本 俊亮; 柏木 仁; 武隈 洋; 菅原 満, 日本薬剤学会年会講演要旨集, 40年会, 130, 130, May 2025
  (公社)日本薬剤学会, Japanese
• 小児ループス腎炎におけるTDMに基づくミコフェノール酸の個別治療戦略
  梨本 俊亮, ファルマシア, 61, 2, 159, 159, 2025
  ループス腎炎(lupus nephritis: LN)は全身性エリテマトーデス(systemic lupus erythematosus: SLE)に合併して生じる腎障害であり，その約10～30％が末期腎不全に移行し生命予後を悪化させる．LNにおける薬物治療は，ステロイドを第一選択薬として用い，重症例ではシクロホスファミド静注，あるいはミコフェノール酸モフェチル(mycophenolate mofetil: MMF)のいずれかを併用する．このうちMMFは経口剤であり，その侵襲性の低さから欧米諸国で汎用されている．MMFは生体内で速やかにミコフェノール酸 (mycophenolic acid: MPA) に加水分解されるが，MPAは体内動態の個体内，個体間変動が大きく，投与量と血中濃度が相関しないことが知られている．そのため，TDMに基づきMMFの投与量を最適化する必要がある．成人患者においては，投与後12時間までの血中濃度曲線下面積(area under the curve_0-12: AUC_0-12)を30～45µg・hr/mL以上に保つことで良好な腎予後を得られたことがこれまでに報告されている．しかしながら，小児患者における目標血中濃度については症例数が限られており，これまで明らかにされていなかった．今回は小児LN患者を対象に，MPAの血中濃度と治療効果および副作用発現との関連性を解析したZhangらの論文を紹介する．
  
  なお，本稿は下記の文献に基づいて，その研究成果を紹介するものである.
  
  1) van Gelder T. et al., Nephrol. Dial. Transplant., 30, 560-564(2015).
  
  2) Łuszczyńska P., Pawiński T., Ther. Drug Monit., 37, 711-717(2015).
  
  3) Zhang L. et al., Rheumatology, 63, SI180-SI187(2024)., 公益社団法人 日本薬学会, Japanese
• Establishment of a monolayer culture system for jejunal epithelial cells that allows evaluation of transport activity
  笹川義樹; 神嶋莉穂; 柏木仁; 佐藤夕紀; 梨本俊亮; 武隈洋; 菅原満; 菅原満, 日本薬学会年会要旨集(Web), 145th, 2025
• Evaluation of whether middle molecules are substrates for P-gp using P-gp-overexpressing cells
  柏木仁; 山田隼大; 王子谷健太; 佐藤夕紀; 梨本俊亮; 渡邉瑞貴; 廣瀬友靖; 廣瀬友靖; 岩月正人; 岩月正人; 砂塚敏明; 砂塚敏明; 金光佳世子; 石井真由美; 渡邊恵里; 宮地弘幸; 武隈洋; 菅原満; 菅原満, 日本薬学会年会要旨集(Web), 145th, 2025
• Regulation of the activity of amino acid transporter SNAT4 by platelets
  柏木仁; 佐藤夕紀; 梨本俊亮; 今井俊吾; 武隈洋; 菅原満; 菅原満, 日本薬学会年会要旨集(Web), 145th, 2025
• Development and validation of the prediction score for augmented renal clearance in Japanese intensive care units
  三上龍生; 三上龍生; 今井俊吾; 早川峰司; 佐藤夕紀; 柏木仁; 梨本俊亮; 菅原満; 武隈洋, 日本薬学会年会要旨集(Web), 145th, 2025
• Decrease in mycophenolic acid plasma level by sacubitril/valsartan in lupus nephritis patient: a case report
  梨本俊亮; 宮前祐士; 樋口一世; 河野通仁; 多田麻里亜; 渥美達也; 菅原満; 菅原満; 武隈洋, 日本薬学会年会要旨集(Web), 144th, 2024
• ヒアルロン酸4,6,8糖の同時定量法の確立
  佐藤夕紀; 高林直央; 青柳空馬; 梨本俊亮; 柏木仁; 武隈洋; 菅原満; 菅原満, 日本薬剤学会年会講演要旨集(CD-ROM), 39th, 2024
• 国内の医療データベースを利用した0-1歳小児患者におけるバンコマイシン誘発性腎機能障害のリスク要因分析
  宮井貴之; 武隈洋; 柏木仁; 佐藤夕紀; 梨本俊亮; 菅原満; 今井俊吾, 日本薬学会年会要旨集, Mar. 2023
  Japanese, Summary national conference
• 肝機能障害患者に対するボリコナゾールの初期投与設計におけるAlbumin-Bilirubinスコアの有用性検証
  梨本俊亮; 今井俊吾; 菅原満; 菅原満; 武隈洋, TDM研究, 40, 2, 175, 175, 2023
  (一社)日本TDM学会, Japanese
• Development of a method of simultaneous determination of orally administered hyaluronan oligosaccharides
  高林直央; 佐藤夕紀; 柏木仁; 梨本俊亮; 武隈洋; 菅原満; 菅原満, バイオメディカル分析科学シンポジウム講演要旨集, 35th, 2023
• エチノマイシンとその誘導体の LC-MS/MS による定量法の確立と体内動態解析
  齋藤香英; 武隈洋; 柏木仁; 佐藤夕紀; 梨本俊亮; 市川聡; 菅原満, 第35回北海道薬物作用談話会 プログラム・要旨集, Aug. 2022
  Japanese, Summary national conference
• コレステロールトランスポーターNPC1L1を介した食事由来脂質の消化管吸収動態解析
  梨本俊亮, 日本医療薬学会年会講演要旨集(Web), 32, 2022
• Transport via Niemann-Pick C1 Like 1 contributes to the intestinal absorption of ubiquinone
  梨本俊亮, DMPK Newsletter, 35, 6, Dec. 2020, [Lead author]
  Japanese, Others
• Xenopus laevis oocyteを用いたコレステロールトランスポーターNiemann-Pick C1-Like1(NPC1L1)発現系の構築
  梨本俊亮; 八木沙織; 武田直樹; 野中美玖; 武隈洋; 菅原満; 菅原満; 佐藤夕紀, トランスポーター研究会年会抄録集, 15th, 2020
• Xenopus laevis oocytesを用いたNiemann-Pick C1-Like 1(NPC1L1)発現系の最適化
  八木 沙織; 梨本 俊亮; 佐藤 夕紀; 鷲見 正人; 武隈 洋; 菅原 満, 日本薬学会年会要旨集, 139年会, 4, 68, 68, Mar. 2019
  (公社)日本薬学会, Japanese
• 新しい錠剤包装ESOP(easy seal open pack)の使用感とその改良に向けた調査研究
  佐藤夕紀; 梨本俊亮; 武隈洋; 平野卓哉; 野田敏宏; 須田範行; 井関健; 盛本修司; 菅原満, 日本医療薬学会年会講演要旨集(Web), 28, 2018
• 脂質異常症治療薬エゼチミブによるα-トコフェロールの消化管吸収抑制とその回避策
  梨本 俊亮; 佐藤 夕紀; 鷲見 正人; 武隈 洋; 菅原 満, 日本薬学会年会要旨集, 136年会, 4, 55, 55, Mar. 2016
  (公社)日本薬学会, Japanese
• エゼチミブ(ゼチーア)が機能性食品成分α-トコフェロールの吸収に与える影響
  梨本 俊亮; 佐藤 夕紀; 鷲見 正人; 武隈 洋; 菅原 満, 日本薬剤学会年会講演要旨集, 30年会, 131, 131, May 2015
  (公社)日本薬剤学会, Japanese

• 唾液中薬物濃度モニタリングが適用可能な薬物のスクリーニング方法の検討
  原康輔; 武隈洋; 梨本俊亮; 佐藤夕紀; 柏木仁; 菅原満
  第39回北海道薬物作用談話会, 23 Aug. 2026, Japanese, Oral presentation
  23 Aug. 2026 - 23 Aug. 2026
• レテルモビルがボリコナゾールの代謝に与える影響
  田崎陽大; 梨本俊亮; 佐藤夕紀; 柏木仁; 武隈洋; 菅原満
  第39回北海道薬物作用談話会, 23 Aug. 2026, Japanese, Oral presentation
  23 Aug. 2026 - 23 Aug. 2026
• ヒアルロン酸2糖の定量を目的とした分析条件の最適化
  青栁空馬; 佐藤夕紀; 梨本俊亮; 柏木仁; 武隈洋; 菅原満
  日本薬学会北海道支部第153回例会, 30 May 2026, Japanese, Oral presentation
  30 May 2026 - 30 May 2026
• 循環器用薬サクビトリルバルサルタン併用によるミコフェノール酸血中濃度低下の機序解析
  梨本俊亮; 尾上尚吾; 佐藤夕紀; 柏木仁; 武隈洋; 菅原満
  日本薬学会第146年会, 27 Mar. 2026, Japanese, Oral presentation
  26 Mar. 2026 - 29 Mar. 2026
• 膠原病患者におけるミコフェノール酸のクリアランス予測に向けた 血清クレアチニンおよびシスタチンCに基づく 母集団薬物動態モデリング
  梨本俊亮; 宮前祐士; 小野寺駿; 菅原満; 武隈洋
  第1回日本炎症免疫薬学会学術集会, 14 Mar. 2026, Japanese, Oral presentation
  14 Mar. 2026 - 14 Mar. 2026
• レプチンがヒトリンパ管内皮細胞の細胞膜透過性に与える影響
  佐藤夕紀; 船戸美汐; 柏木仁; 梨本俊亮; 武隈洋; 菅原満
  第35回日本医療薬学会年会, 23 Nov. 2025, Japanese, Poster presentation
  22 Nov. 2025 - 24 Nov. 2025
• 非小細胞肺がん患者におけるドセタキセル誘発性浮腫の要因分析－多施設共同後ろ向き観察研究－
  山下慎介; 齋藤佳敬; 平手大輔; 若井香鈴; 玉木慎也; 今井俊吾; 柏木仁; 佐藤夕紀; 梨本俊亮; 榊原純; 清水康; 木下一郎; 武隈洋; 菅原満
  第35回日本医療薬学会年会, 22 Nov. 2025, Japanese, Oral presentation
  22 Nov. 2025 - 24 Nov. 2025
• 血清クレアチニン値のラウンドアップ法が重症患者の腎機能評価に与える時間的影響
  三上龍生; 今井俊吾; 早川峰司; 柏木仁; 佐藤夕紀; 梨本俊亮; 菅原満; 武隈洋
  第30回 札幌病院薬剤師会会員発表会, 15 Nov. 2025, Japanese, Oral presentation
  15 Nov. 2025 - 15 Nov. 2025
• 未分画ヘパリン投与下の APTT と 抗Ⅹa活性 の不一致に対する腎機能の影響：探索的後ろ向き観察研究
  三上龍生; 早川峰司; 今井俊吾; 斉藤智誉; 佐藤夕紀; 柏木仁; 梨本俊亮; 菅原満; 武隈洋
  第19回 日本腎臓病薬物療法学会学術集会・総会, 02 Nov. 2025, Japanese, Oral presentation
  01 Nov. 2025 - 02 Nov. 2025
• ARNI内服中に尿中Cペプチドとインスリン分泌能指標の乖離を認めた2型糖尿病の1例
  小野寺駿; 宮前祐士; 樋口一世; 梨本俊亮; 中村昭伸; 菅原満; 武隈洋
  日本糖尿病学会北海道地方会, 19 Oct. 2025, Japanese, Oral presentation
  19 Oct. 2025 - 19 Oct. 2025
• 肝がん細胞トランスポーターの輸送活性に与える血小板の影響
  柏木仁; 佐藤夕紀; 梨本俊亮; 今井俊吾; 武隈洋; 菅原満
  第76回日本薬理学会北部会, 05 Oct. 2025, Japanese, Oral presentation
  04 Oct. 2025 - 05 Oct. 2025
• Saliva-based therapeutic drug monitoring of oxazolidinone antibiotics
  Yuki Inoue; Hitoshi Kashiwagi; Yuki Sato; Shunsuke Nashimoto; Tsutomu Endo; Masahiko Takahata; Miki Komatsu; Mitsuru Sugawara; Yoh Takekuma
  IATDMCT 2025, Sep. 2025, English, Poster presentation
  21 Sep. 2025 - 24 Sep. 2025
• Development of a method of LC/MS-MS for simultaneous determination of hyaluronan oligosaccharides
  Yuki Sato; Nao Takabayashi; Kuma Aoyagi; Shunsuke Nashimoto; Hitoshi Kashiwagi; Yoh Takekuma; Mitsuru Sugawara
  IATDMCT 2025, Sep. 2025, English, Poster presentation
  21 Sep. 2025 - 24 Sep. 2025
• 博士課程卒業後のキャリアパス ～実務家教員の立場から～
  梨本俊亮
  令和7年度国公立大学高度薬学人材育成ワークショップ, 20 Sep. 2025, Japanese, Nominated symposium
  20 Sep. 2025 - 20 Sep. 2025, [Invited]
• ミコフェノール酸モフェチルの薬物動態に循環器用薬サクビトリルバルサルタンが与える影響
  尾上尚吾; 梨本俊亮; 佐藤夕紀; 柏木仁; 武隈洋; 菅原満
  第38回北海道薬物作用談話会, 24 Aug. 2025, Japanese, Oral presentation
  24 Aug. 2025 - 24 Aug. 2025
• 肝機能障害患者におけるAlbumin-bilirubin （ALBI）スコアを用いた母集団薬物動態解析に基づくボリコナゾール投与量の最適化
  梨本俊亮; 菅原満; 武隈洋
  医療薬学フォーラム2025/第33回クリニカルファーマシーシンポジウム, 29 Jun. 2025, Japanese, Poster presentation
  28 Jun. 2025 - 29 Jun. 2025
• リネゾリド投与による嘔気嘔吐発現メカニズムの探索～セロトニン産生腫瘍細胞株QGP-1を用いた検討～
  堤竹蔵; 柏木仁; 佐藤夕紀; 今井俊吾; 梨本俊亮; 菅原満; 武隈洋
  医療薬学フォーラム2025/第33回クリニカルファーマシーシンポジウム, 29 Jun. 2025, Japanese, Poster presentation
  28 Jun. 2025 - 29 Jun. 2025
• 小腸オルガノイドapical-basal反転培養方法の確立
  浅川綾汰; 佐藤夕紀; 柏木仁; 梨本俊亮; 武隈洋; 菅原満
  第8回フレッシャーズ・カンファランス, 22 Jun. 2025, Japanese, Oral presentation
  21 Jun. 2025 - 22 Jun. 2025
• アミノ酸トランスポーターSNAT4を介したエンドサイトーシスによる基質修飾リポソームの取り込み
  松山琳空; 佐藤夕紀; 藤田聡; 丸山真吾; 梨本俊亮; 柏木仁; 武隈洋; 菅原満
  日本薬剤学会第40年会, 23 May 2025, Japanese, Oral presentation
  22 May 2025 - 24 May 2025
• ループス腎炎患者におけるサクビトリルバルサルタンとの併用によるミコフェノール酸の血中濃度低下とその機序の解明
  梨本俊亮
  第79回医薬品相互作用研究会シンポジウム, 18 May 2025, Japanese, Nominated symposium
  18 May 2025 - 18 May 2025, [Invited]
• P糖タンパク質の異なる基質認識部位に結合する化合物の構造の探索
  大家悠寿; 山田隼大; 王子谷健太; 柏木仁; 佐藤夕紀; 梨本俊亮; 宮地弘幸; 武隈洋; 菅原満
  日本薬学会北海道支部第152回例会, 17 May 2025, Japanese, Oral presentation
  17 May 2025 - 17 May 2025
• 血小板によるアミノ酸トランスポーターSNAT4の輸送活性変動
  柏木仁; 佐藤夕紀; 梨本俊亮; 今井俊吾; 武隈洋; 菅原満
  日本薬学会第145年会, 28 Mar. 2025, Japanese, Oral presentation
  26 Mar. 2025 - 29 Mar. 2025
• 日本の集中治療室における過大腎クリアランス予測スコアの開発と検証
  三上龍生; 今井俊吾; 早川峰司; 佐藤夕紀; 柏木仁; 梨本俊亮; 菅原満; 武隈洋
  日本薬学会第145年会, 28 Mar. 2025, Japanese, Oral presentation
  26 Mar. 2025 - 29 Mar. 2025
• ベースラインの血小板数がリネゾリド誘発性血小板減少症の発現に与える影響
  井上優希; 柏木仁; 佐藤夕紀; 梨本俊亮; 菅原満; 武隈洋
  日本薬学会第145年会, 28 Mar. 2025, Japanese, Oral presentation
  26 Mar. 2025 - 29 Mar. 2025
• P-gp基質性評価のためのP-gp高発現細胞樹立とその中分子化合物への応用
  柏木仁; 山田隼大; 王子谷健太; 佐藤夕紀; 梨本俊亮; 渡邉瑞貴; 廣瀬友靖; 岩月正人; 砂塚敏明; 金光佳世子; 石井真由美; 渡邊恵里; 宮地弘幸; 武隈洋; 菅原満
  日本薬学会第145年会, 27 Mar. 2025, Japanese, Public symposium
  26 Mar. 2025 - 29 Mar. 2025
• トランスポーターの輸送活性評価が可能な空腸上皮細胞単層培養系の確立
  笹川義樹; 神嶋莉穂; 柏木仁; 佐藤夕紀; 梨本俊亮; 武隈洋; 菅原満
  日本薬学会第145年会, 27 Mar. 2025, Japanese, Oral presentation
  26 Mar. 2025 - 29 Mar. 2025
• 非小細胞肺がん患者におけるドセタキセル誘発性浮腫の要因分析
  山下慎介; 齋藤佳敬; 今井俊吾; 柏木仁; 佐藤夕紀; 梨本俊亮; 榊原純; 清水康; 木下一郎; 武隈洋; 菅原満
  第14回日本臨床腫瘍薬学会 学術大会2025, 15 Mar. 2025, Japanese, Oral presentation
  15 Mar. 2025 - 16 Mar. 2025
• 2種の過大腎クリアランス(ARC)予測スコアの時系列比較による精度検証
  三上龍生; 早川峰司; 今井俊吾; 佐藤夕紀; 柏木仁; 梨本俊亮; 菅原満; 武隈洋
  第34回日本医療薬学会年会, 04 Nov. 2024, Japanese, Poster presentation
  02 Nov. 2024 - 04 Nov. 2024
• 抗酸化物質コエンザイムQ10のバンコマイシン誘発性腎障害抑制効果
  武内咲知枝; 佐藤夕紀; 梨本俊亮; 柏木仁; 武隈洋; 菅原満
  第34回日本医療薬学会年会, 04 Nov. 2024, Japanese, Oral presentation
  02 Nov. 2024 - 04 Nov. 2024
• EGFP付加によるNPC1L1のコレステロール取り込み量への影響
  小林万梨花; 柏木仁; 佐藤夕紀; 梨本俊亮; 武隈洋; 菅原満
  第37回北海道薬物作用談話会, 18 Aug. 2024, Japanese, Oral presentation
  18 Aug. 2024 - 18 Aug. 2024
• 空腸上皮細胞単層培養系によるトランスポーターの輸送活性評価
  笹川義樹; 神嶋莉穂; 柏木仁; 佐藤夕紀; 梨本俊亮; 武隈洋; 菅原満
  日本薬学会北海道支部第151回例会(第71回北海道薬学大会), 06 Jul. 2024, Japanese, Oral presentation
  06 Jul. 2024 - 07 Jul. 2024
• 抗酸化物質投与によるバンコマイシン誘発性腎障害抑制の評価
  武内咲知枝; 佐藤夕紀; 梨本俊亮; 柏木仁; 武隈洋; 菅原満
  日本薬学会北海道支部第151回例会(第71回北海道薬学大会), 06 Jul. 2024, Japanese, Oral presentation
  06 Jul. 2024 - 07 Jul. 2024
• ヒアルロン酸４, ６, ８糖の同時定量法の確立
  佐藤夕紀; 髙林直央; 青栁空馬; 梨本俊亮; 柏木仁; 武隈洋; 菅原満
  日本薬剤学会第39年会, 25 May 2024, Japanese, Oral presentation
  23 May 2024 - 25 May 2024
• サクビトリルバルサルタンとの併用によりミコフェノール酸の血中濃度が顕著に低下したループス腎炎患者の1例
  梨本俊亮; 宮前祐士; 樋口一世; 河野通仁; 多田麻里亜; 渥美達也; 菅原満; 武隈洋
  日本薬学会第144年会, 30 Mar. 2024, Japanese, Poster presentation
  28 Mar. 2024 - 31 Mar. 2024
• 牛乳成分を用いた乳剤化によるコエンザイムQ10の吸収改善効果
  山内佑紀恵; 八巻義朗; 佐藤夕紀; 柏木 仁; 梨本俊亮; 武隈 洋; 菅原 満
  第33回日本医療薬学会年会, 04 Nov. 2023, Japanese, Oral presentation
  03 Nov. 2023 - 05 Nov. 2023
• Monitoring saliva and plasma concentrations of tedizolid and linezolid in rats
  Yuki Inoue; Yuki Sato; Hitoshi Kashiwagi; Shunsuke Nashimoto; Mitsuru Sugawara; Yoh Takekuma
  第33回日本医療薬学会年会, 03 Nov. 2023, English, Poster presentation
  03 Nov. 2023 - 05 Nov. 2023
• エトポシドの誘導体化によるP糖タンパク質の基質認識性への影響
  山口ひとみ; 柏木仁; 佐藤夕紀; 梨本俊亮; 宮地弘幸; 武隈洋; 菅原満
  第36回北海道薬物作用談話会, 20 Aug. 2023, Japanese, Oral presentation
  20 Aug. 2023
• 経口投与されたヒアルロン酸オリゴ糖の同時定量法開発
  髙林直央; 佐藤夕紀; 柏木仁; 梨本俊亮; 武隈洋; 菅原満
  第35回バイオメディカル分析科学シンポジウム, 28 Jul. 2023, Japanese, Oral presentation
  28 Jul. 2023 - 29 Jul. 2023
• Usefulness of the Albumin-Bilirubin Score in Determining the Initial Dose of Voriconazole for Patients with Liver Cirrhosis
  Shunsuke Nashimoto; Shungo Imai; Mitsuru Sugawara; Yoh Takekuma
  The 39th Annual Meeting for The Japanese Society of Therapeutic Drug Monitoring, 24 Jun. 2023, Japanese, Oral presentation
  24 Jun. 2023 - 25 Jun. 2023
• 牛乳の利用によるCoQ10吸収改善の可能性の探索
  山内佑紀恵; 八巻義朗; 佐藤夕紀; 柏木 仁; 梨本俊亮; 武隈 洋; 菅原 満
  日本薬学会北海道支部第150回例会(第70回北海道薬学大会), 20 May 2023, Japanese, Oral presentation
  20 May 2023 - 21 May 2023
• 国内の医療データベースを利用した0－1歳小児患者におけるバンコマイシン誘発性腎機能障害のリスク要因分析
  宮井貴之; 武隈洋; 柏木仁; 佐藤夕紀; 梨本俊亮; 菅原満; 今井俊吾
  日本薬学会第139年会, 27 Mar. 2023, Japanese, Oral presentation
  25 Mar. 2023 - 28 Mar. 2023
• Pharmacokinetic Analysis of Dietary Lipids via Cholesterol Transporter NPC1L1
  梨本俊亮
  The 32nd Annual Meeting of the Japanese Society of Pharmaceutical Health Care and Sciences, 25 Sep. 2022, Japanese, Invited oral presentation
  23 Sep. 2022 - 25 Sep. 2022, [Invited]
• エチノマイシンとその誘導体の LC-MS/MS による定量法の確立と体内動態解析
  齋藤香英; 武隈洋; 柏木仁; 佐藤夕紀; 梨本俊亮; 市川聡; 菅原満
  第35回北海道薬物作用談話会, 21 Aug. 2022, Japanese, Oral presentation
  21 Aug. 2022 - 21 Aug. 2022
• Xenopus laevis oocyteを用いたコレステロールトランスポーターNiemann-Pick C1-Like 1(NPC1L1)発現系の構築
  梨本 俊亮; 八木 沙織; 武田 直樹; 野中 美玖; 武隈 洋; 菅原 満; 佐藤 夕紀
  トランスポーター研究会15回年会, Oct. 2020, Japanese, Oral presentation
• コレステロールトランスポーターNPC1L1を介したコエンザイムQ10の消化管吸収
  梨本 俊亮; 竹川 悠人; 佐藤 夕紀; 武隈 洋; 菅原 満
  トランスポーター研究会14回年会, Jul. 2019, Japanese, Poster presentation
• Xenopus laevis oocytesを用いたNiemann-Pick C1-Like 1(NPC1L1)発現系の最適化
  八木 沙織; 梨本 俊亮; 佐藤 夕紀; 鷲見 正人; 武隈 洋; 菅原 満
  日本薬学会第139年会, Mar. 2019, Japanese, Oral presentation
• エゼチミブによるα-トコフェロールの消化管吸収抑制とその回避策
  梨本 俊亮; 佐藤 夕紀; 武隈 洋; 菅原 満
  第30回ビタミンE研究会, Jan. 2019, Japanese, Oral presentation
• 新しい錠剤包装ESOP(easy seal open pack)の使用感とその改良に向けた調査研究
  佐藤 夕紀; 梨本 俊亮; 武隈 洋; 平野 卓哉; 野田 敏宏; 須田 範行; 井関 健; 盛本 修司; 菅原 満
  第28回日本医療薬学会年会, Nov. 2018, Japanese, Poster presentation
• 機能性食品成分ルテインとコエンザイムQ10の製剤学的工夫による消化管吸収改善
  佐藤 夕紀; 定村 樹; 八巻 義朗; 横山 さや香; 梨本 俊亮; 武隈 洋; 菅原 満
  第12回次世代を担う若手医療薬科学シンポジウム, Sep. 2018, Japanese, Oral presentation
• ルテインの製剤化による消化管吸収改善
  定村 樹; 佐藤 夕紀; 梨本 俊亮; 鷲見 正人; 武隈 洋; 菅原 満
  日本薬学会北海道支部第144回例会, May 2017, Japanese, Oral presentation
• 脂質異常症治療薬エゼチミブによるα-トコフェロールの消化管吸収抑制とその回避策-ラットおよびヒト血漿中濃度推移からのアプローチ
  梨本 俊亮; 佐藤 夕紀; 鷲見 正人; 武隈 洋; 菅原 満
  第30回北海道TDM研究会研究発表会, Nov. 2016, Japanese, Oral presentation
• 脂質異常症治療薬エゼチミブと 機能性食品成分α-トコフェロールの相互作用に関する研究
  梨本俊亮
  北海道大学大学院生命科学院入学式 「先輩からのメッセージ」, 05 Apr. 2016, Japanese, Public discourse
  05 Apr. 2016 - 05 Apr. 2016, [Invited]
• 脂質異常症治療薬エゼチミブによるα-トコフェロールの消化管吸収抑制とその回避策
  梨本 俊亮; 佐藤 夕紀; 鷲見 正人; 武隈 洋; 菅原 満
  日本薬学会第136年会, Mar. 2016, Japanese, Oral presentation
• α-トコフェロールの吸収動態に及ぼすエゼチミブの影響
  佐藤 夕紀; 梨本 俊亮; 武隈 洋; 菅原 満
  第27回ビタミンE研究会, Jan. 2016, Japanese, Oral presentation
• エゼチミブ (ゼチーア®) が機能性食品成分α-トコフェロールの吸収に与える影響
  梨本 俊亮; 佐藤 夕紀; 鷲見 正人; 武隈 洋; 菅原 満
  日本薬剤学会第30年会, May 2015, Japanese, Oral presentation

• 医療情報解析演習, 2024年, 学士課程, 薬学部
• 実務実習事前実習, 2024年, 学士課程, 薬学部
• OSCE対応演習, 2024年, 学士課程, 薬学部

• Jan. 2026 - Present
  日本化学療法学会
• Jan. 2026 - Present
  日本炎症免疫薬学会
• Feb. 2023 - Present
  The Japanese Society of Therapeutic Drug Monitoring
• Apr. 2020 - Present
  日本病院薬剤師会
• Jun. 2019 - Present
  The Japanese Society of Pharmaceutical Health Care and Sciences
• Nov. 2015 - Present
  The Pharmaceutical Society of Japan
• Jun. 2013 - Present
  北海道TDM研究会

• Development of voriconazole dosing regimens using ALBI score based on population pharmacokinetic analysis
  Grants-in-Aid for Scientific Research
  01 Apr. 2023 - 31 Mar. 2027
  梨本 俊亮
  Japan Society for the Promotion of Science, Grant-in-Aid for Early-Career Scientists, Hokkaido University, 23K14404

• 実務実習指導薬剤師養成WS タスクフォース
  Feb. 2024 - Present
  Lecturer
• 北海道大学薬学部ＳＰ（模擬患者）会
  May 2022 - Present
  Planner, Organizing member
• 松前町立松前病院支援事業
  17 Aug. 2025 - 22 Aug. 2025
  Organizing member

• Jul. 2023 - Jun. 2029
  日本病院薬剤師会 病院薬学認定薬剤師
• May 2020 - May 2023
  日本薬剤師研修センター 認定薬剤師